PARPis after PARPis in patients with recurrent epithelial ovarian cancer: a single institutional experience.

ABSTRACT:

Objective

To explore the clinical efficacy of PARPis maintenance treatment rechallenge in patients with recurrent epithelial ovarian cancer (EOC) in China.

Methods

We included patients diagnosed with primary EOC who received 2 lines of PARPis maintenance treatment after achieving complete response (CR) or partial response (PR) with the previous chemotherapies. The patients' full medical records were included in this study. Clinical and pathologic variables, treatment modalities, and outcomes were assessed. We investigated the treatment patterns and time to next treatment (TTNT).

Results

A total of 31 ovarian cancer patients in our center were included. Among these patients, 20 of them (64.5%) had BRCA1/2 gene mutations. The median duration of PARPi1 and PARPi2 in the

SUBMITTER: Yuan H 

PROVIDER: S-EPMC12465649 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature